CloneID: 7A4
Antigen Long Description: 7A4 was generated by hyperimmunizing mice with recombinant gamma-interferon-treated LAN-1 neuroblastoma cells.
Origin Pub PMID: 9309424
Buffer Composition: PBS only.
Specificity Statement: 7A4 binds to GD2: GD2+ neuroblastoma cell lines and melanomas, small-cell lung carcinomas, rhabdomyosarcomas, Ewings sarcomas, Wilm's tumors and retinoblastomas also expressing GD2. GD2- cell lines or GD2- peripheral blood cells are not bound by the antibody. The antibody and the scFv cross-react weakly with GD3 and GM2. GD2 is a target for tumor therapy due to its high level of expression in the majority of neuroblastoma and melanoma cells, and poor levels of expression in normal tissues.
Application Notes (Clone): 7A4 is able to lyse tumour cells by complement-mediated cytotoxicity (lytic dose ~10 ng) and can perform in vitro direct binding of labelled mAb to living and glutaraldehyde-fixed cells. Shows strong binding to all neuroblastomas tested in addition to other GD2-expressing cells such as melanomas, small-cell lung carcinomas, rhabdomyosarcomas, Ewings sarcomas, Wilm's tumors and retinoblastomas. TLC analysis can be used to confirm the antibody target antigen. The 7A4 scFv possesses the same specificity as the full-length antibody but slightly weaker binding affinity. The scFv has been used in IF studies (PMID: 9309424).